DS 5573a

Drug Profile

DS 5573a

Alternative Names: DS-5573; DS-5573a

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD276 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 01 May 2017 Discontinued - Phase-I for Solid tumours (Metastatic disease) in Japan (IV) (Daiichi Sankyo pipeline, May 2017)
  • 01 Jan 2017 Daiichi Sankyo terminates a phase I trial in Solid tumours (Metastatic disease) in Japan (IV) (NCT02192567)
  • 14 Jul 2014 Daiichi Sankyo plans a phase I trial for Solid tumours in Japan (NCT02192567)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top